Yuanyuan Zhao, MD

Yuanyuan Zhao, MD, discusses phase 1b data for the PD-1/VEGF bispecific RC148 (ABBV-1480) plus chemotherapy in first-line NSCLC, how it is engineered differently from ivonescimab and pumitamig, and what the global phase 3 program needs to show.